An interventional study of HED-Start in End Stage Renal Disease on Dialysis, End Stage Renal Failure on Dialysis and End Stage Renal Disease, sponsored by Nanyang Technological University. Recruiting at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Nanyang Technological University · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Kidney Failure, Chronic with a site in Singapore — 2 open to participants now, 2 under way, none of them phase 3. Kidney Failure, Chronic · Singapore.
Among the 17 studies in Kidney Failure, Chronic with a site in Singapore, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2021, is one of 9 with no phase, and was the 12th registered.
2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.
Browse Kidney Failure, Chronic studies →2 of the 17 studies in Kidney Failure, Chronic with a site in Singapore are open now. Recruiting first, the newest first:
The University of Queensland · Sites in Singapore, Australia, Brazil and 6 more countries
Ages 18+
A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →
Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 148 is above the median of 57 across 1,573 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 99 across the 16 interventional studies, 35 across the 1 observational. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
Nanyang Technological University is the lead sponsor of 54 studies on the registry; 18 are open to participants now.
Nanyang Technological University has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Kidney Failure, Chronic with a site in Singapore, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Hemodialysis patients often experience barriers and misperceptions that hinder adjustment to life on dialysis. This study seeks to explore a group-based intervention (titled HED-Start) developed to improve self-care and emotional wellbeing among incident hemodialysis patients.
There are potentially modifiable psychosocial barriers and misperceptions about life on dialysis that hinder adjustment outcomes. It is hypothesized that these may include: poor understanding on what is needed or 'how to implement treatment principles', misperceptions related to disease and treatment, catastrophizing beliefs about impact of dialysis and low level of confidence on ability to manage treatment regime and renegotiate life roles as a "dialysis patient".
This study seeks to explore the feasibility and acceptability of implementing a two-arm parallel randomized controlled trial of a group-based intervention (titled HED-Start). HED-Start is specifically developed to reduce psychological distress and support self-care and self-management outcomes in incident hemodialysis patients.
Drawing on self-management and motivational interviewing principles paradigm, the HED-Start program aims to facilitate acquisition of skills and knowledge to support and improve self-care and emotional adjustment outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the intervention arm will undergo 4 sessions of the HED-Start program. Each session is 2 hours long and will be conducted fortnightly.
Behavioral: HED-Start
Participants assigned to the standard care arm will proceed with routine standard care.
The HED-Start Program is a cognitive-behavioral intervention based on self-management and motivational interviewing principles.
Change in Anxiety and Depression (HADS) scores from baseline
Hospital Anxiety and Depression Scale (HADS). The HADS comprises two subscales (anxiety; depression) and can be totaled to produce an overall scale score. Scores range from 0 to 21 for each subscale, and from 0 to 42 for the overall score. Higher scores are indicative of worse anxiety and depression symptoms.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in Quality of life (WHOQOL-BREF) scores from baseline
World Health Organization Quality of Life instrument (WHOQOL-BREF). Two global items (overall quality of life; general health) and two subscales (psychological health; social relationships) from the WHOQOL-BREF are used. Global scores range from 1 to 5, while subscale scores range from 4 to 20. Higher scores indicate better quality of life.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in kidney disease-related quality of life (KDQOL-SF) scores from baseline
Kidney Disease Quality of Life instrument (KDQOL-SF). The Burden of Kidney Disease subscale from the KDQOL-SF will be administered. Scores range from 0 to 100, with a higher score reflecting better quality of life.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in Illness Perception scores from baseline
Brief Illness Perception Questionnaire (BIPQ). The BIPQ consists of 8 subscales (i.e., Consequence, Timeline, Identity, Personal Control, Treatment Control, Concern, Coherence, and Emotional Representation). Subscale scores range from 0 to 10, with higher scores reflective of more negative illness perceptions.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in Positive and Negative Affect scores from baseline
Scale of Positive and Negative Experience (SPANE). The SPANE comprises 6 items assessing positive affect and 6 items assessing negative affect. Subscale scores range from 6 to 30. Higher scores in the Positive and Negative affect subscale indicate greater positive and negative affect respectively.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in Self-Efficacy for Managing Chronic Disease 6-item Scale scores from baseline
Self-Efficacy for Managing Chronic Disease 6-item Scale. The overall scale score ranges from 1 to 10. Higher scores reflect greater self-efficacy.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in Benefit finding in hemodialysis (BFS) scores from baseline
Benefit Finding Scale (BFS). Two subscales (personal growth; acceptance) and an overall score can be computed. All scores range from 1 to 4, with a higher score reflecting a greater extent of benefit finding.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in Resilience scores from baseline
2-item Connor-Davidson Resilience Scale (CD-RISC-2). The CD-RISC-2 score ranges from 0 to 8. Higher scores indicate greater resilience.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Change in Health Education Impact Questionnaire scores from baseline
Health Education Impact Questionnaire (heiQ). Six subscales from the heiQ (Positive and Active Engagement in Life, Skill and Technique Acquisition, Constructive Attitudes and Approaches, Self-Monitoring and Insight, Health Services Navigation, and Social Integration and Support) will be used to assess other self-management skills. Scores range from 1 to 4. Higher scores indicate greater proficiency with the relevant skill domain.
Time frame: Participants will be assessed at two time points: [T1] Baseline and [T2] 3 months post-randomization
Plan to share: Yes — All deidentified IPD that underlie results in a publication will be available upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan
Ran from Jan 2021 to primary completion in Oct 2022, 21 months.
Of 349 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's 21 months is close to that.
Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanyang Technological University